ALXN
Alexion Pharmaceuticals Inc
Alexion Pharmaceuticals Inc historical holders
total: 4
Miller Value Partners Alexion Pharmaceuticals Inc transactions over time
- Total transactions:
- 13
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 6
- Held since:
- 2016 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2020 Q1
Bill Miller has been an institutional investor in Alexion Pharmaceuticals Inc (ALXN) since 2016 Q4. According to 2026 Q1 report, Bill Miller doesn't hold any shares. The fund/company first acquired ALXN in 2016 Q4, initially purchasing 99,710 shares. Since the initial investment, Miller Value Partners has made 12 more transactions in this position.
When did Bill Miller exit their ALXN position?
Bill Miller no longer holds Alexion Pharmaceuticals Inc (ALXN). They sold off their entire position in 2020 Q1, closing out an investment that began in 2016 Q4.
When did Bill Miller first invest in ALXN?
Bill Miller first invested in Alexion Pharmaceuticals Inc (ALXN) in 2016 Q4 at the reported quarter-end price of $122.35 per share, acquiring 99,710 shares in their initial purchase.
What is Bill Miller's average cost basis for ALXN?
Based on historical transaction data, Bill Miller's estimated cost basis for Alexion Pharmaceuticals Inc (ALXN) is approximately $121.95 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $121.95
- Weighted AVG sell price:
- $108.87
ALXN transactions history by Miller Value Partners
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q1
|
0.00%
|
$108.15
|
-100% (-388,380)
|
|||
|
2019 Q4
|
1.50%
|
$108.15
|
-13.46% (-60,400)
|
|||
|
2019 Q2
|
2.35%
|
$130.98
|
+0.25% (+1,100)
|
|||
|
2019 Q1
|
2.41%
|
$135.18
|
-0.10% (-455)
|
|||
|
2018 Q4
|
1.99%
|
$97.36
|
-0.15% (-690)
|
|||
|
2018 Q3
|
2.03%
|
$139.01
|
+1.46% (+6,480)
|
|||
|
2018 Q2
|
2.06%
|
$124.15
|
+5.05% (+21,280)
|
|||
|
2018 Q1
|
2.01%
|
$111.46
|
-3.62% (-15,800)
|
|||
|
2017 Q4
|
2.26%
|
$119.59
|
-1.70% (-7,560)
|
|||
|
2017 Q3
|
2.87%
|
$140.29
|
-1.40% (-6,300)
|
|||
|
2017 Q2
|
2.49%
|
$121.67
|
+25.66% (+92,025)
|
|||
|
2017 Q1
|
2.25%
|
$121.24
|
+259.74% (+258,990)
|
|||
|
2016 Q4
|
0.65%
|
$122.35
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.